| 199.92 0.18 (0.09%) | 06-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 233.5 | 1-year : | 272.73 |
| Resists | First : | 199.91 | Second : | 233.5 |
| Pivot price | 199.02  |
|||
| Supports | First : | 193.64 | Second : | 189.75 |
| MAs | MA(5) : | 199.49 |
MA(20) : | 198.36 |
| MA(100) : | 150.62 |
MA(250) : | 96 |
|
| MACD | MACD : | 3.9  |
Signal : | 5 |
| %K %D | K(14,3) : | 100 |
D(3) : | 93.9 |
| RSI | RSI(14): 84 | |||
| 52-week | High : | 199.91 | Low : | 25.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RXDX ] has closed Bollinger Bands are 94.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 200.03 - 201.06 | 201.06 - 201.84 |
| Low: | 197.49 - 198.58 | 198.58 - 199.43 |
| Close: | 198.2 - 200.02 | 200.02 - 201.42 |
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Fri, 16 Jun 2023
Merck Completes Acquisition of Prometheus Biosciences, Inc. - Yahoo Finance
Tue, 30 May 2023
Prometheus Biosciences Stock: 8.5% IRR, Closing In A Month (RXDX) - Seeking Alpha
Sat, 29 Apr 2023
With 67% ownership, Prometheus Biosciences, Inc. (NASDAQ:RXDX) boasts of strong institutional backing - Yahoo Finance
Mon, 17 Apr 2023
Merck Acquires Prometheus Biosciences for $10.8 Billion - Investopedia
Mon, 17 Apr 2023
Latham & Watkins Advises Prometheus Biosciences in US$10.8 Billion Acquisition by Merck - Latham & Watkins LLP -
Mon, 17 Apr 2023
Merck to buy Prometheus Biosciences for about $11 billion - Reuters.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 3.323e+007 (%) |
| Held by Institutions | 16.6 (%) |
| Shares Short | 4,900 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6161e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 64.7 % |
| Return on Equity (ttm) | -20.1 % |
| Qtrly Rev. Growth | 4e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -133 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.71 |
| Dividend | 0 |
| Forward Dividend | 4.68e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|